PMID- 11249748
OWN - NLM
STAT- MEDLINE
DCOM- 20010412
LR  - 20051116
IS  - 1464-8431 (Print)
IS  - 1464-8431 (Linking)
VI  - 2
IP  - 6
DP  - 2000 Dec
TI  - Technology evaluation: PRO-542, Progenics Pharmaceuticals inc.
PG  - 697-702
AB  - Progenics's rCD4-IgG2 (PRO-542) is a recombinant fusion protein, which has been 
      developed using the company's Universal Antiviral Binding (UnAB) technology, and 
      is in phase I/II clinical trials for the treatment of human immunodeficiency 
      virus type I (HIV-1) infection [273391]. At the beginning of 1997, Progenics 
      received a Phase II Small Business Innovation Research Program (SBIR) grant from 
      the National Institute of Allergy and Infectious diseases (NIAID) to fund the 
      development of PRO-542 [236048]. A further grant of $2.7 million was awarded in 
      August 1998 for the clinical evaluation of PRO-542 and other anti-HIV therapies 
      [294200]. Progenics is collaborating with the Aaron Diamond AIDS Research Center 
      (ADARC) in New York and the Center for Disease Control and Prevention in Atlanta 
      [178410]. In February 2000, Progenics and Genzyme Transgenics Corp signed an 
      agreement to continue the development of a transgenic source of PRO-542. Genzyme 
      will develop transgenic goats that produce PRO-542 in their milk in exchange for 
      undisclosed fees and milestone payments. Genzyme will supply PRO-542 to Progenics 
      for clinical trials with a possibility for eventual commercial supply [357291]. 
      Following on from this, in October 2000, Progenics received an SBIR grant to fund 
      a two-year project with Genzyme Transgenics into the development of 
      cost-effective methods for the manufacture of PRO-542, by optimization of the 
      production of the drug in the milk of transgenic dairy animals [385982]. In 
      August 2000, Punk, Ziegel & Company predicted that Progenics Pharmaceuticals will 
      become sustainably profitable in 2003 following the launch of PRO-542 and GMK 
      (Progenics Pharmaceuticals) in 2002 [390063].
FAU - Mukhtar, M
AU  - Mukhtar M
AD  - Dorrance H Hamilton Laboratories, Department of Medicine, Jefferson Medical 
      College, Thomas Jefferson University, Philadelphia, PA 19107, USA. 
      Muhammad.Mukhtar@mail.tju.edu
FAU - Parveen, Z
AU  - Parveen Z
FAU - Pomerantz, R J
AU  - Pomerantz RJ
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Mol Ther
JT  - Current opinion in molecular therapeutics
JID - 100891485
RN  - 0 (Anti-HIV Agents)
RN  - 0 (CD4 Immunoadhesins)
RN  - 0 (CD4-IgG(2))
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/adverse effects/metabolism/*therapeutic use
MH  - Biotechnology
MH  - CD4 Immunoadhesins/adverse effects/metabolism/*therapeutic use
MH  - HIV Infections/*drug therapy/immunology/*prevention & control
MH  - HIV-1
MH  - Humans
MH  - Immunotherapy
RF  - 38
EDAT- 2001/03/16 10:00
MHDA- 2001/04/17 10:01
CRDT- 2001/03/16 10:00
PHST- 2001/03/16 10:00 [pubmed]
PHST- 2001/04/17 10:01 [medline]
PHST- 2001/03/16 10:00 [entrez]
PST - ppublish
SO  - Curr Opin Mol Ther. 2000 Dec;2(6):697-702.